Aclaris Therapeutics (ACRS) Competitors $1.38 +0.05 (+3.76%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. AKBA, TYRA, GHRS, CGEM, RLAY, STOK, SAGE, MRVI, MGTX, and URGNShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Akebia Therapeutics (AKBA), Tyra Biosciences (TYRA), GH Research (GHRS), Cullinan Therapeutics (CGEM), Relay Therapeutics (RLAY), Stoke Therapeutics (STOK), Sage Therapeutics (SAGE), Maravai LifeSciences (MRVI), MeiraGTx (MGTX), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Akebia Therapeutics Tyra Biosciences GH Research Cullinan Therapeutics Relay Therapeutics Stoke Therapeutics Sage Therapeutics Maravai LifeSciences MeiraGTx UroGen Pharma Aclaris Therapeutics (NASDAQ:ACRS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Does the MarketBeat Community prefer ACRS or AKBA? Akebia Therapeutics received 34 more outperform votes than Aclaris Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Aclaris Therapeutics an outperform vote while only 63.17% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38866.67% Underperform Votes19433.33% Akebia TherapeuticsOutperform Votes42263.17% Underperform Votes24636.83% Do institutionals and insiders hold more shares of ACRS or AKBA? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ACRS or AKBA more profitable? Akebia Therapeutics has a net margin of -27.07% compared to Aclaris Therapeutics' net margin of -136.65%. Akebia Therapeutics' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Akebia Therapeutics -27.07%N/A -20.57% Which has more risk & volatility, ACRS or AKBA? Aclaris Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Which has preferable earnings & valuation, ACRS or AKBA? Akebia Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M7.98-$88.48M-$1.51-0.91Akebia Therapeutics$160.18M3.55-$51.92M-$0.33-7.30 Does the media prefer ACRS or AKBA? In the previous week, Aclaris Therapeutics had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 12 mentions for Aclaris Therapeutics and 9 mentions for Akebia Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.00 beat Akebia Therapeutics' score of 0.87 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ACRS or AKBA? Aclaris Therapeutics presently has a consensus price target of $11.67, indicating a potential upside of 745.41%. Akebia Therapeutics has a consensus price target of $6.63, indicating a potential upside of 174.90%. Given Aclaris Therapeutics' higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryAclaris Therapeutics and Akebia Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.43M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.657.4422.4818.48Price / Sales7.98242.70394.56103.59Price / CashN/A65.8538.1834.62Price / Book0.626.516.774.25Net Income-$88.48M$143.21M$3.22B$248.23M7 Day Performance8.66%1.98%1.48%0.89%1 Month Performance-6.76%6.89%3.99%3.53%1 Year Performance9.52%-2.52%16.15%5.08% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics3.15 of 5 stars$1.38+3.8%$11.67+745.4%+14.0%$149.43M$18.72M-2.65100Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap DownAKBAAkebia Therapeutics4.078 of 5 stars$2.07+0.5%$6.50+214.0%+91.3%$489.00M$160.18M-9.00430Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsTYRATyra Biosciences2.0175 of 5 stars$9.06+1.6%$30.83+240.3%-39.8%$481.00MN/A-5.6320Upcoming EarningsNews CoveragePositive NewsGHRSGH Research1.9534 of 5 stars$9.17+0.8%$30.86+236.5%-13.0%$477.10MN/A-11.6110Upcoming EarningsNews CoverageCGEMCullinan Therapeutics2.6536 of 5 stars$8.10+2.7%$34.80+329.6%-69.3%$473.96MN/A-2.8530Analyst RevisionNews CoverageRLAYRelay Therapeutics2.0021 of 5 stars$2.75+2.2%$18.36+567.8%-48.9%$466.19M$10.01M-1.05330Upcoming EarningsGap DownSTOKStoke Therapeutics3.5145 of 5 stars$8.61+12.0%$24.67+186.5%-11.5%$465.61M$36.56M-4.10100Upcoming EarningsNews CoverageHigh Trading VolumeSAGESage Therapeutics3.724 of 5 stars$7.44+0.1%$8.81+18.4%-47.7%$457.42M$41.24M-1.13690Earnings ReportAnalyst RevisionNews CoverageMRVIMaravai LifeSciences4.1581 of 5 stars$1.77flat$6.34+258.4%-75.4%$450.18M$259.19M-1.08610Upcoming EarningsOptions VolumeMGTXMeiraGTx4.5461 of 5 stars$5.65+4.4%$24.50+333.6%+45.3%$445.53M$33.28M-4.67300Upcoming EarningsShort Interest ↑Positive NewsURGNUroGen Pharma4.2834 of 5 stars$9.66-0.1%$32.86+240.1%-15.8%$445.27M$90.40M-3.07200Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Akebia Therapeutics Competitors Tyra Biosciences Competitors GH Research Competitors Cullinan Therapeutics Competitors Relay Therapeutics Competitors Stoke Therapeutics Competitors Sage Therapeutics Competitors Maravai LifeSciences Competitors MeiraGTx Competitors UroGen Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRS Stock Free ACRS Stock Alerts